NASDAQ: CADLCandel Therapeutics Inc Stock
$5.46+0.02 (+0.37%)
Updated Apr 18, 2024
CADL Price
$5.46
Fair Value Price
$0.44
Market Cap
$160.24M
52 Week Low
$0.66
52 Week High
$11.40
P/E
-4.17x
P/B
12.57x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$37.94M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.23
Operating Cash Flow
-$34M
Beta
0.71
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CADL Overview
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer patients. Its pipeline includes CAN-2409, in Phase II clinical trials for the treatment of pancreatic cancer, Phase III clinical trials for the treatment of prostate cancer, Phase II clinical trials for the treatment of lung cancer, and Phase Ib/II clinical trials (completed) for the treatment of high-grade glioma. The company is also developing CAN-3110, in Phase I clinical trials for the treatment of recurrent glioblastoma. Candel Therapeutics was incorporated in 2003 and is based in Needham, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CADL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CADL ($5.46) is overvalued by 1,148.81% relative to our estimate of its Fair Value price of $0.44 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CADL ($5.46) is not significantly undervalued (1,148.81%) relative to our estimate of its Fair Value price of $0.44 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CADL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CADL due diligence checks available for Premium users.
Be the first to know about important CADL news, forecast changes, insider trades & much more!
CADL News
Valuation
CADL fair value
Fair Value of CADL stock based on Discounted Cash Flow (DCF)
Price
$5.46
Fair Value
$0.44
Overvalued by
1,148.81%
CADL ($5.46) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CADL ($5.46) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CADL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CADL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.17x
Industry
15.68x
Market
41.33x
CADL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
12.57x
Industry
5.76x
CADL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CADL's financial health
Profit margin
Revenue
$0.0
Net Income
-$11.1M
Profit Margin
0%
CADL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$41.2M
Liabilities
$28.5M
Debt to equity
2.23
CADL's short-term assets ($36.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CADL's short-term assets ($36.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CADL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.4M
Investing
-$27.0k
Financing
-$121.0k
CADL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CADL vs Biotech Stocks
Candel Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.